Silver Book Fact

Disease specific status and generic health status improvements from TAVR and SAVR

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to 22 point improvement on a 100 point scale) and in generic health status (3.9 to 5.1 point improvement on a 36 point scale).

Baron S, Arnold S, Wang K, et al. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial. JAMA Cardiology. 2017; 2(8): 837-45. https://jamanetwork.com/journals/jamacardiology/article-abstract/2635358

Reference

Title
Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial
Publication
JAMA Cardiology
Publication Date
2017
Authors
Baron S, Arnold S, Wang K, et al
Volume & Issue
Volume 2, Issue 8
Pages
837-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • TAVR improves quality of life in SAS patients
     
  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).